 Previously reported data showed cell-activating receptors for complement-C5a and leukotriene B4 LTB4 in the retina. Nomacopan inhibits C5a and LTB4 signalling via these receptors. NEW YORK and LONDON, Jan. 27, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, announces new preclinical data indicating that nomacopan significantly reduced both retinal inflammation and intraocular VEGF. 